# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Clear Street analyst Kaveri Pohlman initiates coverage on Ventyx Biosciences (NASDAQ:VTYX) with a Buy rating and announces P...
Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(...